Cargando…

USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study

BACKGROUND AND AIMS: Patients with advanced liver fibrosis owing to chronic hepatitis C virus genotype 1 represent a difficult-to-treat group even if a protease inhibitor is added to pegylated interferon alpha and ribavirin. Therefore, only patients with a high chance of cure should be treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankova, Sona, Jirsa, Milan, Merta, Dusan, Neroldova, Magdalena, Urbanek, Petr, Senkerikova, Renata, Spicak, Julius, Sperl, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687952/
https://www.ncbi.nlm.nih.gov/pubmed/26719699
http://dx.doi.org/10.2147/TCRM.S94010
_version_ 1782406695923744768
author Frankova, Sona
Jirsa, Milan
Merta, Dusan
Neroldova, Magdalena
Urbanek, Petr
Senkerikova, Renata
Spicak, Julius
Sperl, Jan
author_facet Frankova, Sona
Jirsa, Milan
Merta, Dusan
Neroldova, Magdalena
Urbanek, Petr
Senkerikova, Renata
Spicak, Julius
Sperl, Jan
author_sort Frankova, Sona
collection PubMed
description BACKGROUND AND AIMS: Patients with advanced liver fibrosis owing to chronic hepatitis C virus genotype 1 represent a difficult-to-treat group even if a protease inhibitor is added to pegylated interferon alpha and ribavirin. Therefore, only patients with a high chance of cure should be treated with interferon-based treatment. PATIENTS AND METHODS: Expression of IFNG, IFNLR1, and interferon-sensitive genes CXCL9, IFI16, IFI27, ISG15, and USP18 in peripheral blood mononuclear cells was assessed before and during the initial 12 weeks of treatment. The studied group consisted of 26 treatment-experienced patients of average age of 50 years with advanced liver fibrosis compared to seven healthy volunteers. Fourteen patients were treated with pegylated interferon alpha 2b, ribavirin, and boceprevir and 12 patients with telaprevir. The overall sustained virological response (SVR) rate was 69% (18/26). RESULTS: A significant difference in the initial expression (median, interquartile range [IQR]) of CXCL9 2.9×, IQR: 1.7–12.4 vs 1.2×, IQR: 0.5–1.8; (P=0.01) IFNG 7.3×, IQR: 1.7–32.6 vs 0.7×, IQR: 0.4–1.3; P=0.002 and USP18 3.7×, IQR: 2.1–7.7 vs 1.4×, IQR: 0.9–1.6; (P=0.03) was found between the SVR and non-SVR groups. Expression of all analyzed genes was progressively increasing during the first 12 weeks of therapy, but a significant difference between SVR and non-SVR group was found only in USP18 expression at week 12 (P=0.001). Initial expression of four genes predicted SVR in univariate analysis (CXCL9 [OR: 12.00, 95% CI: 1.21–118.89], IFI27 [OR: 12.00, 95% CI: 1.21–118.89], IFNG [OR: 10.50, 95% CI: 1.50–73.67], USP18 [OR: 21.00, 95% CI: 2.05–215.18]). In multivariate analysis, only the initial expression of USP18 was identified as a predictor of SVR (P=0.047). CONCLUSION: Initial expression of USP18 and the course of its activation could be a reliable predictor of SVR achievement.
format Online
Article
Text
id pubmed-4687952
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46879522015-12-30 USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study Frankova, Sona Jirsa, Milan Merta, Dusan Neroldova, Magdalena Urbanek, Petr Senkerikova, Renata Spicak, Julius Sperl, Jan Ther Clin Risk Manag Original Research BACKGROUND AND AIMS: Patients with advanced liver fibrosis owing to chronic hepatitis C virus genotype 1 represent a difficult-to-treat group even if a protease inhibitor is added to pegylated interferon alpha and ribavirin. Therefore, only patients with a high chance of cure should be treated with interferon-based treatment. PATIENTS AND METHODS: Expression of IFNG, IFNLR1, and interferon-sensitive genes CXCL9, IFI16, IFI27, ISG15, and USP18 in peripheral blood mononuclear cells was assessed before and during the initial 12 weeks of treatment. The studied group consisted of 26 treatment-experienced patients of average age of 50 years with advanced liver fibrosis compared to seven healthy volunteers. Fourteen patients were treated with pegylated interferon alpha 2b, ribavirin, and boceprevir and 12 patients with telaprevir. The overall sustained virological response (SVR) rate was 69% (18/26). RESULTS: A significant difference in the initial expression (median, interquartile range [IQR]) of CXCL9 2.9×, IQR: 1.7–12.4 vs 1.2×, IQR: 0.5–1.8; (P=0.01) IFNG 7.3×, IQR: 1.7–32.6 vs 0.7×, IQR: 0.4–1.3; P=0.002 and USP18 3.7×, IQR: 2.1–7.7 vs 1.4×, IQR: 0.9–1.6; (P=0.03) was found between the SVR and non-SVR groups. Expression of all analyzed genes was progressively increasing during the first 12 weeks of therapy, but a significant difference between SVR and non-SVR group was found only in USP18 expression at week 12 (P=0.001). Initial expression of four genes predicted SVR in univariate analysis (CXCL9 [OR: 12.00, 95% CI: 1.21–118.89], IFI27 [OR: 12.00, 95% CI: 1.21–118.89], IFNG [OR: 10.50, 95% CI: 1.50–73.67], USP18 [OR: 21.00, 95% CI: 2.05–215.18]). In multivariate analysis, only the initial expression of USP18 was identified as a predictor of SVR (P=0.047). CONCLUSION: Initial expression of USP18 and the course of its activation could be a reliable predictor of SVR achievement. Dove Medical Press 2015-12-17 /pmc/articles/PMC4687952/ /pubmed/26719699 http://dx.doi.org/10.2147/TCRM.S94010 Text en © 2015 Frankova et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Frankova, Sona
Jirsa, Milan
Merta, Dusan
Neroldova, Magdalena
Urbanek, Petr
Senkerikova, Renata
Spicak, Julius
Sperl, Jan
USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
title USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
title_full USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
title_fullStr USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
title_full_unstemmed USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
title_short USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
title_sort usp18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis c, genotype 1: a pilot study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687952/
https://www.ncbi.nlm.nih.gov/pubmed/26719699
http://dx.doi.org/10.2147/TCRM.S94010
work_keys_str_mv AT frankovasona usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy
AT jirsamilan usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy
AT mertadusan usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy
AT neroldovamagdalena usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy
AT urbanekpetr usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy
AT senkerikovarenata usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy
AT spicakjulius usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy
AT sperljan usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy